ea0021p204 | Endocrine tumours and neoplasia | SFEBES2009
Burton Hannah
, Annamalai Anand K
, Dean Andrew
, Kovacs Kalman
, Antoun Nagui
, Kirollos Ramez W
, Simpson Helen L
, Jeffries Sarah J
, Burnet Neil G
, Gurnell Mark
Background: Pituitary carcinoma occurs in ~0.2% of resected pituitary tumours, and carries a poor prognosis (mean survival <4 years), with standard chemotherapeutic regimens showing limited efficacy. However, recent evidence suggests that temozolomide, an orally active alkylating agent used principally in the management of glioblastoma, may also be effective in controlling aggressive/invasive pituitary adenomas/carcinomas. Low levels of expression of the DNA-repair enzyme ...